Association Between Cerebrospinal Fluid Biomarkers and Age-related Brain Changes in Patients with Normal Pressure Hydrocephalus.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 06 2020
04 06 2020
Historique:
received:
31
03
2020
accepted:
16
05
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
20
1
2021
Statut:
epublish
Résumé
Our study aimed to: 1)investigate the diagnostic utility of CSF Aβ42, t-tau, and p-tau to differentiate normal-pressure-hydrocephalus(NPH) from Alzheimer's-disease(AD) and normal-controls; and 2)investigate if age and ventricular size affect the levels of CSF biomarkers in NPH patients. We recruited 131 participants: (a)Suspected-NPH: 72 with ventriculomegaly and clinical symptoms of NPH. These participants were then divided into two groups of 1)Probable-NPH (N = 38) and 2)Unlikely-NPH (N = 34) based on whether participants experienced gait improvement after removal of a large amount of CSF; (b)AD group: 30 participants with CSF biomarkers and cognitive symptoms consistent with AD; (c)Control-group: 29 participants who were cognitively and functionally normal. Lower levels of CSF Aβ42 and p-tau were observed in the probable-NPH compared to the normal controls(444.22 ± 163.3 vs. 1213.75 ± 556.5; and 26.05 ± 9.2 vs. 46.16 ± 13.3 pg/mL; respectively). Lower levels of CSF p-tau and t-tau were found in the probable-NPH compared to the AD(26.05 ± 9.2 vs. 114.95 ± 28.2; and 193.29 ± 92.3 vs. 822.65 ± 311.5 pg/mL; respectively) but the CSF-Aβ42 was low in both the probable-NPH and AD. CSF-Aβ42 correlated with age and Evans-index only in the probable-NPH(r = 0.460, p = 0.004; and r = -0.530, p = 0.001; respectively). Our study supports the hypothesis that age-related atrophy results in better Aβ42 clearance in the CSF because of the increase in the interstitial space.
Identifiants
pubmed: 32499567
doi: 10.1038/s41598-020-66154-y
pii: 10.1038/s41598-020-66154-y
pmc: PMC7272629
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9106Références
Jeppsson, A., Zetterberg, H., Blennow, K. & Wikkelsø, C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology 80, 1385–1392 (2013).
doi: 10.1212/WNL.0b013e31828c2fda
Kapaki, E. et al. Cerebrospinal fluid tau, phospho‐tau181 and β‐amyloid1− 42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. European journal of neurology 14, 168–173 (2007).
doi: 10.1111/j.1468-1331.2006.01593.x
Ågren‐Wilsson, A. et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta neurologica Scandinavica 116, 333–339 (2007).
doi: 10.1111/j.1600-0404.2007.00890.x
Graff-Radford, N. R. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology 83, 1573–1575 (2014).
doi: 10.1212/WNL.0000000000000916
Xie, L. et al. Sleep drives metabolite clearance from the adult brain. science 342, 373–377 (2013).
doi: 10.1126/science.1241224
Relkin, N., Marmarou, A., Klinge, P., Bergsneider, M. & Black, P. M. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 57, S2–4 (2005).
doi: 10.1227/01.NEU.0000168185.29659.C5
Synek, V., Reuben, J. & Du Boulay, G. Comparing Evans’ index and computerized axial tomography in assessing relationship of ventricular size to brain size. Neurology 26, 231–231 (1976).
doi: 10.1212/WNL.26.3.231
Sand, T. et al. Idiopathic normal pressure hydrocephalus: the CSF tap‐test may predict the clinical response to shunting. Acta neurologica scandinavica 89, 311–316 (1994).
doi: 10.1111/j.1600-0404.1994.tb02640.x
Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1, 213–225 (2004).
doi: 10.1602/neurorx.1.2.213
Blennow, K. et al. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer’s & Dementia 11, 58–69 (2015).
doi: 10.1016/j.jalz.2014.02.004
Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53, 695–699 (2005).
doi: 10.1111/j.1532-5415.2005.53221.x
Freedman, M. et al. The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment. Alzheimer’s research & therapy 10, 65 (2018).
doi: 10.1186/s13195-018-0382-y
Jack, C. R. Jr et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine 27, 685–691 (2008).
doi: 10.1002/jmri.21049
Hulstaert, F. et al. Improved discrimination of AD patients using β-amyloid (1−42) and tau levels in CSF. Neurology 52, 1555–1555 (1999).
doi: 10.1212/WNL.52.8.1555
Maddalena, A. et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Archives of neurology 60, 1202–1206 (2003).
doi: 10.1001/archneur.60.9.1202
Toma, A. K., Holl, E., Kitchen, N. D. & Watkins, L. D. Evans’ index revisited: the need for an alternative in normal pressure hydrocephalus. Neurosurgery 68, 939–944 (2011).
doi: 10.1227/NEU.0b013e318208f5e0
Team, R. C. R: A Language and Environment for Statistical Computing. (2018).
Shingala, M. C. & Rajyaguru, A. Comparison of post hoc tests for unequal variance. International Journal of New Technologies in Science and Engineering 2, 22–33 (2015).